

|            |  |                                 |                                 | (Rs in Lacs)                     |
|------------|--|---------------------------------|---------------------------------|----------------------------------|
| Sr. No.    | Particulars  | For the Qtr ended<br>30.06.2011 | For the Qtr ended<br>30.06.2010 | For the Year ended<br>31.03.2011 |
|            |  | (Unaudited)                     | (Unaudited)                     | (Audited)                        |
|            | INCOME   |                                 |                                 |                                  |
| 1)         | Net Sales/Income from Operations   | 8,397.16                        | 8,794.51                        | 30,999.49                        |
|            | Foreign Exchange Gain (Net)  | -                               | 101.94                          | 19.16                            |
|            | Other Operating Income   | 177.34                          | 1 <b>5</b> 8.47                 | 575,66                           |
|            | Total Income   | 8,574.50                        | 9,054.92                        | 31,594.31                        |
| 2)         | Expenditure  |                                 |                                 |                                  |
| 2)         | a. (Increase)/Decrease in Stocks of  |                                 |                                 |                                  |
|            | WIP & Finished/Traded Goods  | 170.57                          | (161.50)                        | (307,58)                         |
|            | b. Cost of Materials   | 2,592,56                        | 3,004.95                        | 11,008.35                        |
|            | c. Purchase of Traded Goods  | 1,254.25                        | 1,159.39                        | 4,062.12                         |
|            | d. Staff Cost  | 1,517.74                        | 1,302.80                        | 5,717,68                         |
|            | e. Depreciation/Amortisation   | 235.29                          | 219.88                          | 905.71                           |
|            | f. Foreign Exchange Loss(Net)  | 6.39                            | -                               | -                                |
|            | g. Other Expenditure   | 2,474.68                        | 2,439,93                        | 10,126.32                        |
|            | Total Expenditure  | 8,251.48                        | 7,965.45                        | 31,512.60                        |
| 3)         | Profit from Operations before Other Income, Interest &                     | 323.02                          | 1,089.47                        | 81.71                            |
|            | Exceptional Items (1-2)  |                                 |                                 | ,                                |
| 4)         | Other Income   | <u> </u>                        | -                               | -                                |
| 5)         | Profit before Interest & Exceptional Items                                 | 323.02                          | 1,089.47                        | 81.71                            |
| 6)         | Interest (Net)   | 713.58                          | 514.40                          | 2,304.93                         |
| 7)         | Profit after Interest but before Exceptional Items                         | (390.56)                        | 575.07                          | (2,223.22)                       |
| 8)         | Exceptional Items  | -                               |                                 | -                                |
| 9)         | Profit / (Loss) from Ordinary Activities before Tax                        | (390.56)                        | 575.07                          | (2,223.22)                       |
| 10)        | Tax Expense  | 0.33                            | 0.26                            | 3.48                             |
| 11)        | Net Profit /(Loss) from Ordinary Activities after 'l'ax                    | (390.89)                        | 574.81                          | (2,226.70)                       |
| 12)<br>13) | Extraordinary Item (Net of Tax Expense ) Net Profit /(Loss) for the Period | (390.89)                        | -<br>574.81                     | (2.22(.20)                       |
| 1.0)       | Tect From 7 (Loss) for the Ferrott   | (390.09)                        | 3/4.61                          | (2,226.70)                       |
| 14)        | Paid - up Equity Share Capital (Face value of Rs.10/- each)                | 1,468.93                        | 1,468.93                        | 1,468.93                         |
| 15)        | Reserves & Surplus (excluding Revaluation Reserve)                         | <i>'</i>                        | , i                             | 8,854.26                         |
| 16)        | EPS (Rs.) - Basic & Diluted before and after extraordinary items ( not     | (2.66)                          | 3.91                            | (15.16)                          |
| ,          | annualised)  | (2.00)                          | 5.71                            | (13.10)                          |
| 17)        | Public Shareholding-   | i                               |                                 |                                  |
|            | - Number of shares   | 10,190,556                      | 8,5 <i>7</i> 5,010              | 10,193, <b>7</b> 35              |
|            | - Percentage of shareholding   | 69.37%                          | 58.38%                          | 69.40%                           |
| 18)        | Promoters and Promoter Group Shareholding:-                                |                                 |                                 |                                  |
|            | a) Plodged / Encumbered  |                                 |                                 |                                  |
|            | - Number of shares   | 3,812,500                       | 788,500                         | 788,500                          |
|            | - Percentage of shares (as a % of the total shareholding of promoter       | 17.52%                          | 12.90%                          | 17.54%                           |
|            | and promoter group)  |                                 |                                 |                                  |
|            | - Percentage of shares (as a % of the total share capital of the company)  | 5.36%                           | 5.37%                           | 5.36%                            |
|            | b) Non - Encumbered  |                                 |                                 |                                  |
|            | - Number of shares   | 686,230                         | 5,325,776                       | 3,707,051                        |
|            | - Percentage of shares (as a % of the total shareholding of promoter       | 82.48%                          | 87.10%                          | 82.46%                           |
|            | and promoter group)  |                                 |                                 |                                  |
|            | - Percentage of shares (as a % of the total share capital of the           | 25 <i>.27</i> %                 | 36.25%                          | 25,24%                           |
|            | company)   |                                 |                                 |                                  |

## Notes :-

- The above financial results have been reviewed by the Audit Committee and have been taken on record at the meeting of the Board of Directors of the Company held on 12th August, 2011.
- 2) The Company has only one segment of activity namely "Pharmaceuticals".
- 3) The market price of the equity shares of the Company being less than the exercise price in respect of various outstanding options to subscribe to equity shares, the aforesaid options are considered to be anti-dilutive.
- 4) Erstwhile The Pharmaceutical Products of India Limited (PPIL) merged with the Company pursuant to the Scheme of Revival cum Merger (the Scheme) approved vide order dated 24th April, 2007 by the Board for Industrial and Financial Reconstruction (BIFR) u/s 18 and other applicable provisions of the Sick Industrial Companies (Special Provisions) Act, 1985 (SICA) w.e.f. 1st April, 2006, being the appointed date.

Subsequently in response to a suit filed by one of the unsecured creditors of crstwhile PPIL, challenging the Scheme, the Hon'ble Supreme Court vide its order dated 16th May, 2008, has set aside the above referred BIFR order and remitted the matter back to BIFR for considering afresh as per the provisions of SICA.

The matter is now under consideration of the BIFR. In the meanwhile, the Company has sought legal opinion and has been advised to maintain status quo ante with respect to the merger under the said Scheme and that it should take further steps only on the basis of the fresh BIFR order.

In view of the above, the Company has maintained a status quo. However, all actions taken by the Company pursuant to the sanctioned scheme shall remain subject to and without prejudice to the orders that may be passed by the BIFR while considering the case afresh pursuant to the directions of the Hon'ble Supreme Court in its order dated 16th May, 2008.

- 5) As on 30th June, 2011, the balance liability on account of oustanding curo denominated FCCB issued by the Company has been restated at an exchange rate of Rs 64.79 and amounts to Rs. 6,142.09 Lacs. The FCCB issue terms stipulate conversion of the Bonds at the pre determined exchange rate of Rs 57.22 at which rate the liability amounts to Rs 5,424.45 Lacs.
- 6) Pro rata premium on outstanding FCCB amounting to Rs 119.99 Lacs and exchange loss of Rs 39.65. Lacs have been charged to the Securities. Premium Account for the quarter ended 30th June 2011.
- 7) The Company has equity investments of Rs. 3,907.71 Lacs in two wholly owned subsidiaries and other company and amount recoverable of Rs.18,470.36 Lacs from them and step down subsidiary. The Company's involvement in the aforesaid entities being of strategic importance and for long term, no provision is considered necessary by the Company at this stage in respect of its investments and amounts recoverable as stated above.
- 8) The Corporate Debt Restructuring (CDR) proposal of the Company, having 30th September ,2010 as the cut off date, has been approved by the CDR Cell vide its Letter of Aproval (LOA) dated, 23rd May, 2011. The effect of the aforesaid restructuring schem will be given upon compliance with the conditions of the scheme.
- 9) During the Quarter, the Company had received and resolved 3 complaints. There was no investor complaint pending at the beginning and at the end of the quarter.
- 10) The Company has applied to the Central Government for waiver of recovery of the excess remuneration of Rs 63.45 Lacs to the executive directors of the Company for the year ended 31st March, 2011. Pending approval of Central Government, the aforesaid amount has been charged to the revenue in the relevent year.

The figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.

Place: Mumbai Date: 12th August, 2011 K. Chandran Vice Chairman